Antineoplastics/cetuximab
-
Upload
duonghuong -
Category
Documents
-
view
212 -
download
0
Transcript of Antineoplastics/cetuximab
Reactions 1362 - 30 Jul 2011
SAntineoplastics/cetuximab
Skin rash and haematological toxicities: 11 casereports
A retrospective study identified 11 patients, aged 37–84years, who developed cetuximab-related skin rashes, andchemotherapy-related haematologic toxicities duringtreatment for squamous cell carcinoma of the head andneck [see table].
The patients started receiving weekly IV cetuximab givenat 400 mg/m2 for 120 mins, followed by 250 mg/m2 for60 min. Additionally, patients were treated withchemotherapy and/or radiotherapy [routes and dosages notstated]. During cetuximab treatment, five patientsexperienced grade I rash, one patient experienced grade IIrash, one patient experienced grade III rash, and twopatients experienced grade IV rash [times to reaction onsetnot stated]. Additionally, chemotherapy-relatedhaematologic toxicities were grade I in four patients, gradeII in one patient, grade III in two patients, and grade IV intwo patients [times to reaction onset not stated]. At lastfollow-up, five patients had died due to diease progression[patient outcomes not stated].
Patient characteristicsPatient/ Additional Rash Haematologicalsex/age (y) chemotherapy toxicities
1/M/84 No Grade IV Grade II2/F/73 Cisplatin Grade III Grade IV3/M/59 Doxycycline, Grade I Grade I
carboplatin4/F/62 Cisplatin Grade I Grade I5/M/57 Yesa Grade 0 Grade I6/M/45 Yesa Grade I Grade I7/M/53 Yesa Grade II Grade 08/M/53 Capecitabine, Grade I Grade IV
nedaplatin,gemcitabine,endostatin
9/M/37 No Grade IV Grade 010/M/66 Yesa Grade 0 Grade III11/M/59 Yesa Grade I Grade IIIa Individual drugs not specified.
Xia L-P, et al. Short-term efficacy of cetuximab combined with radiotherapy orchemotherapy on head and neck cancer: A report of 11 cases. Aizheng 28: No. 9,Jan 2009 - China 803058043
1
Reactions 30 Jul 2011 No. 13620114-9954/10/1362-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved